Article Sidebar
Views PDF: 51
STUDY ON SERUM NGAL LEVELS AND RELATED FACTORS IN PATIENTS WITH ACUTE DECOMPENSATION OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Main Article Content
Abstract
Objectives: To investigate serum NGAL levels and related factors in patients with acute decompensation of chronic heart failure with reduced ejection fraction (HFrEF). Materials and methods: A cross-sectional descriptive study was conducted on HFrEF patients presenting for examination and treatment at Can Tho Central General Hospital from June 2024 to February 2025. Results: A total of 73 patients were included, with a mean age of 67.88 ± 16.94 years, and 60.3% were male. Dyspnea was the most common symptom (71.2%). Chest X-ray findings showed pulmonary congestion in 38.4% and pleural effusion in 23.3% of cases. The mean serum NGAL level was 65.37 ± 29.95 ng/mL. Patients with NYHA class III or higher had higher NGAL levels than those with NYHA class I–II (68.28 ± 30.69 ng/mL versus 47.04 ± 16.02 ng/mL). NGAL levels showed a positive correlation with age (r=0.246, p < 0.05) and systolic blood pressure (r=0.237, p<0.05) and a negative correlation with estimated glomerular filtration rate (r=-0.287, p<0.05). Conclusion: In patients with acute decompensation of chronic heart failure with reduced ejection fraction, dyspnea is the most common symptom. NGAL concentration was positively correlated with age, systolic blood pressure and negatively correlated with glomerular filtration rate.
Article Details
Keywords
acute decompensation heart failure, chronic heart failure with reduced ejection fraction, serum NGAL concentration, some related factors
References
2. Gupta AK, et al. Evidence-based management of acute heart failure. Canadian Journal of Cardiology. 2021. 37(4), p. 621-631.
3. Nassar DK. Neutrophil gelatinase-associated lipocalin (NGAL) role in diagnosis of complications of liver cirrhosis. Egyptian Journal of Medical Microbiology. 2021. 30(2), p. 21-25.
4. Maisel AS, et al. Prognostic utility of plasma neutrophil gelatinase‐associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B‐type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. European journal of heart failure. 2011. 13(8), p. 846-851.
5. Oikonomou E, et al. The association among biomarkers of renal and heart function in patients with heart failure: the role of NGAL. Biomarkers in medicine. 2018. 12(12), p. 1323-1330.
6. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal. 2021. 42(36), p. 3599-3726.
7. Kajimoto K, et al. Etiology of heart failure and outcomes in patients hospitalized for acute decompensated heart failure with preserved or reduced ejection fraction. The American Journal of Cardiology. 2016. 118(12), p. 1881-1887.
8. Van Aelst LN, et al. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. European Journal of Heart Failure. 2018. 20(4), p. 738-747.
9. Warraich HJ, et al. Physical function, frailty, cognition, depression, and quality of life in hospitalized adults≥ 60 years with acute decompensated heart failure with preserved versus reduced ejection fraction: insights from the REHAB-HF trial. Circulation: Heart Failure. 2018. 11(11), p. e005254.
10. De Berardinis B, et al. Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure. Clinical Chemistry Laboratory Medicine. 2015. 53(4), p. 613-621.